📅 PUBMED DAILY TRIAGE — 2026-05-02
Window: 2026-05-01T09:00:00Z → 2026-05-02T09:00:00Z (CRDT) Topics scanned: 10 | Candidates reviewed: ~90+ | Articles classified: 14 High priority: 3 | Standard: 9 | Low/archive: 2 | Unsolicited finds: 0 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)
- TR-2026-05-02-001 · [PMID 42067888] · cfDNA fragmentomics + serum biomarkers ML model for early ovarian cancer detection · 9/10 🔴
- Ovarian cancer early detection: combined cfDNA fragmentomics (CNV, fragment size, Neomer) + CA125/HE4 stacked ML model; AUC 0.968 validation, AUC 0.938 for early-stage FIGO I/II, N=195 (3 cohorts). Near-term screening/pre-op risk stratification potential. (Cell Commun Signal)
Novel Therapeutics (Targeted Therapy / Immunotherapy)
- TR-2026-05-02-002 · [PMID 42067541] · Phase Ib trial validates BCL-2 as a target across heterogeneous castration-resistant prostate cancer · 8/10 🟠
- Multi-platform validation (scRNA-seq, organoids, xenografts, Phase Ib NCT03751436): venetoclax + enzalutamide reduces CTCs in CRPC responders; BCL-2 upregulated across AR+/- CRPC via ARPI relief. Novel drug combination strategy for treatment-resistant solid tumor. (Signal Transduct Target Ther)
Cardiovascular-Metabolic (GLP-1 / SGLT2 / Cardiometabolic Risk)
- TR-2026-05-02-003 · [PMID 42067122] · In-hospital SGLT2i initiation in acute heart failure: meta-analysis 8 RCTs, N=4,096 · 8/10 🟢
- All-cause death RR 0.61 (95%CI 0.47-0.81); worsening HF RR 0.67; CV death RR 0.68; TSA confirms firm mortality evidence; safety comparable to control. Addresses the key clinical question of when to start SGLT2i — immediately actionable. (J Card Fail; Fonarow/Mentz authors)
🟢⚪ STANDARD (5–7) — Top by Topic
Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)
- TR-2026-05-02-004 · [PMID 42067641] · CD135 (FLT3) expression as independent prognostic indicator in de novo AML; prognostic nomogram · 7/10 · Diagnostics
- N=214 + external validation N=78 multicenter; nomogram AUC 0.817/0.722; TKI benefit in high-CD135 FLT3-ITD subset. (Ann Hematol)
- TR-2026-05-02-008 · [PMID 42067967] · Nemtabrutinib (BTK inhibitor) PK/PD modeling in CLL/SLL; 65mg daily dose confirmation; N=578 · 6/10 · Drug Development (CPT Pharmacometrics)
- TR-2026-05-02-013 · [PMID 42067559] · Effector T cell repertoire defines functionally high-risk smoldering myeloma patients; MSKCC biobank · 4/10 [Letter — exception applied] · Diagnostics (Blood Cancer J)
Hematologic malignancies: No high-priority finds today (best 7/10, PMID 42067641)
Early Cancer Detection / Liquid Biopsy
- TR-2026-05-02-006 · [PMID 42066685] · ctDNA guides ICI discontinuation in MSI/dMMR mCRC; 80% ctDNA-neg at protocol completion → 7% progression · 7/10 · Treatment Innovation (ESMO Open; N=84, 48-month FU)
- TR-2026-05-02-009 · [PMID 42055316] · ddPCR cfDNA in pleural effusion for TB diagnosis; sensitivity 83% vs 32% Xpert Ultra; N=91 · 6/10 · Diagnostics (Int J Infect Dis) [deferred resolved]
- TR-2026-05-02-010 · [PMID 42056648] · ADRB1 as novel immune checkpoint in T cell exhaustion in lung cancer; scRNA-seq + TCGA modeling · 5/10 · Drug Development (Discover Oncol) [deferred resolved]
AI/ML in Clinical Diagnostics
- TR-2026-05-02-005 · [PMID 42067698] · Explainable AI for post-EVT stroke prognosis (OPTIMAL-BP RCT); DNN + SBP trajectories, AUC 0.86, N=288, 19 centers · 7/10 · Diagnostics (J Med Syst)
- TR-2026-05-02-011 · [PMID 42067415] · IFCN position statement: AI in clinical neurophysiology (EEG/EMG); safety, transparency, oversight framework · 5/10 · Diagnostics (Clin Neurophysiol)
AI/ML diagnostics: No articles scored ≥8 today (best 7/10, PMID 42067698)
Cardiovascular-Metabolic
- TR-2026-05-02-007 · [PMID 42067840] · Remnant cholesterol × LDL-C interaction in ASCVD: N=3,342; formula-dependent biases (Friedewald vs Sampson-NIH) identified · 6/10 · Diagnostics (Lipids Health Dis)
Aging / Longevity / Population Health
- TR-2026-05-02-012 · [PMID 42067949] · AGE→SIRT1 downregulation→RANKL→osteoclast activation→chondrocyte senescence in OA; multi-omics + mouse validation · 5/10 · Drug Development (Aging Cell)
Aging topic: No high-priority finds today (best 5/10, PMID 42067949)
Precision Oncology / Genomic Medicine
(No high-priority finds today; best candidate 4/10 — off-target results dominated search)
CBC / ML Hematology
(No relevant articles — 9th consecutive sparse window)
Rare Diseases with High Unmet Need
(No standard+ finds today; 42067825 AIP case report: 2/10)
💡 UNSOLICITED FINDS
None qualifying this run. Sentinel scan of 672 broad articles yielded no out-of-watchlist high-signal items.
📊 TODAY'S BREAKDOWN
By research category:
- Early Detection: 2
- Treatment Innovation: 4
- Diagnostics: 5
- Drug Development: 3
- Other: 1 (position statement)
By evidence maturity:
- Validated: 7
- Exploratory: 5
- Potentially Practice-Changing: 2
By watchlist topic (reviewed / kept ≥STANDARD / highest score):
| Topic | Reviewed | Kept (≥5) | Highest |
|---|---|---|---|
| Hematologic malignancies | 10 | 3 | 7 |
| CBC/ML hematology | 10 | 0 | 3 (sparse) |
| Liquid biopsy/ctDNA | 10 | 3 (+1 dup) | 9 |
| AI/ML diagnostics | 10 | 3 | 7 |
| Precision oncology | 10 | 0 | 4 |
| Novel therapeutics | 10 | 3 | 8 |
| Cardiovascular-metabolic | 10 | 3 | 8 |
| Aging/longevity | 10 | 1 | 5 |
| Rare diseases | 8 | 0 | 4 |
| Sentinel scan | 10 | 0 | 3 |
By source type: peer_reviewed: 14 | preprint: 0
Topics with zero 8+ articles this run: Hematologic malignancies, CBC/ML hematology, AI/ML diagnostics (best 7), Precision oncology, Aging/longevity, Rare diseases, Sentinel scan
🔧 RUN NOTES
- Window expansion: NOT triggered (>5 relevant records found).
- Deferred PMIDs from 2026-05-01: 8 total; 3 resolved this run (42056648 STANDARD-5, 42055316 STANDARD-6, 42054842 LOW-2). 5 remain deferred (42056639, 42056619, 42055801, 42055601, 42054834) — could not retrieve full abstracts due to API truncation.
- CBC/ML hematology: 9th consecutive sparse window. No dedicated CBC+ML article identified in this window. Rolling signal suggests this topic requires expanded search or lower-volume topic.
- Precision oncology topic: Top results were basic science studies (ciliopathy zebrafish, CFAP300) that appeared due to broad genomics keyword match; no high-value precision oncology articles in this window.
- PMID 42067559 exception: Letter publication type; included at score 4 cap per exception rule (watchlist-critical topic, MSKCC, Nature-group journal Blood Cancer J). Smoldering myeloma immune profiling is high-interest area.
- Data quality note: All articles reviewed from abstract only; no PMC full text accessed due to publisher paywall status of most articles in this window.
- Alerts sent: 3 Telegram alerts (HIGH priority only): PMIDs 42067888, 42067541, 42067122.